Loading stock data…
$117.80-3.39 (-2.80%)
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Corcept Therapeutics Incorporated in the Healthcare sector is trading at $117.80 with a market capitalization of $12.4B. Wall Street consensus targets $141.00 (5 analysts), implying a +19.7% move over the next 12 months. The stock is currently near its 52-week high of $126.38, remaining 65.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $256.15M↑ | $164.90M↓ | $202.13M↓ | $207.64M↑ | $194.43M |
| Gross Profit | $252.09M↑ | $162.02M↓ | $199.58M↓ | $203.04M↑ | $191.00M |
| Operating Income | $41.30M↑ | -$49.60M↓ | $4.49M↓ | $10.22M↓ | $26.68M |
| Net Income | $42.99M↑ | -$31.76M↓ | $24.29M↑ | $19.67M↓ | $35.15M |
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an...